Embryonal tumor with multilayered rosettes
MONDO:0958119A rare central nervous system embryonal tumor characterized by embryonal cells arranged in multilayered rosettes and displaying one of three morphological patterns: embryonal tumor with abundant neuropil and true rosettes, ependymoblastoma, or medulloepithelioma. The tumors typically have a C19MC alteration or (rarely) a DICER1 mutation and correspond to WHO grade IV. They are mostly localized intracranially, rarely in the spinal cord, and commonly cause signs and symptoms of elevated intracranial pressure, sometimes seizures and focal neurological signs. Most cases occur in children during the first two years of life.
2776 clinical trials for this condition and its sub-types, 8 tagged with Embryonal tumor with multilayered rosettes itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Immune cells engineered to hunt brain tumors in kids
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, deliv…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immune cells engineered to fight brain cancer in kids
Disease control Recruiting nowThis early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …
Phase 1 • Sponsor: Robbie Majzner • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill combo offers hope for kids with relapsed cancers
Disease control Recruiting nowThis study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…
Phase 1/2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for toddlers with aggressive brain cancer: experimental spinal-fluid chemo
Disease control Recruiting nowThis early-phase study tests whether adding chemotherapy directly into the spinal fluid (intrathecal topotecan) followed by maintenance pills is feasible for children under 6 with high-risk embryonal brain tumors. About 15 children will receive this treatment after standard high-…
Early phase 1 • Sponsor: C17 Council • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for kids with rare brain cancer: trial combines chemo and radiation
Disease control Recruiting nowThis study tests a combination of chemotherapy and focused radiation in children newly diagnosed with a rare brain tumor called ETMR. About 70 children will receive standard treatments to see if this approach helps keep the tumor from growing for at least 6 months. The goal is to…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Tailor-Made T-Cells take on childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Rare brain tumor registry launches to unlock secrets of ETMR
Knowledge-focused Recruiting nowThis study creates a worldwide registry for children diagnosed with Embryonal Tumor with Multilayer Rosettes (ETMR), a rare and aggressive brain tumor. Researchers will collect medical records, tumor tissue, and treatment outcomes from up to 100 patients of any age. The goal is t…
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC